Mibrex

Rivaroxaban, the active ingredient in Mibrex, is a Direct Factor Xa inhibitor presented as an unknown/unknown for oral use. It is used to reduce the risk of stroke and systemic embolism in patients with non‑valvular atrial fibrillation, and to treat or prevent deep vein thrombosis and pulmonary embolism, including after orthopedic surgery. GNH USA supplies Mibrex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mibrex (rivaroxaban) acts on the coagulation cascade to prevent pathological clot formation. - Non‑valvular atrial fibrillation: reduces stroke and systemic embolism risk. - Deep vein thrombosis (DVT) and pulmonary embolism (PE): treats acute events and prevents recurrence. - Orthopedic surgery (hip or knee replacement): provides prophylaxis against postoperative DVT.

Rivaroxaban may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Bleeding gums or nosebleeds: mild mucosal bleeding. - Bruising or hematoma: easy bruising at minor trauma sites. - Nausea or dyspepsia: gastrointestinal discomfort. - Headache: mild to moderate intensity.

Serious or Rare Side Effects: - Intracranial hemorrhage: life‑threatening brain bleed. - Spinal or epidural hematoma: risk after neuraxial procedures. - Severe allergic reaction: rash, swelling, or anaphylaxis.

Before initiating rivaroxaban, clinicians should evaluate patient‑specific risk factors and monitor therapy. - Renal function assessment: adjust dose or avoid if severe impairment. - Bleeding risk evaluation: review history of hemorrhage or active ulcers. - Concomitant antiplatelet or NSAID use: increase monitoring for bleeding. - Hepatic impairment: avoid in patients with significant liver disease. - Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Rivaroxaban interacts with several drug classes that can alter its anticoagulant effect.

Major Interactions (Avoid): - Other anticoagulants (e.g., warfarin, heparin): additive bleeding risk. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase plasma levels. - Strong P‑glycoprotein inhibitors (e.g., itraconazole): raise exposure. - Antiplatelet agents (e.g., clopidogrel, aspirin): heightened hemorrhage. - NSAIDs (e.g., ibuprofen, naproxen): exacerbate gastrointestinal bleeding.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., diltiazem, erythromycin): may increase exposure. - Certain antifungals (e.g., fluconazole): modest level rise. - Selective serotonin reuptake inhibitors (e.g., sertraline): monitor for bleeding.